The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 20 | 4,745 |
| Depreciation and amortization | 1,115 | 1,893 |
| Share-based compensation expense | 4,919 | 9,510 |
| Acquired in-process research & development expense | 20,000 | - |
| Other adjustments | -262 | -786 |
| Accounts receivable | 1,813 | 6,534 |
| Inventories | 681 | 3,361 |
| Prepaid expenses and other current assets | -842 | 2,404 |
| Accounts payable & other current liabilities | 2,289 | 2,778 |
| Accrued expenses | -3,572 | 2,077 |
| Other assets and liabilities | 652 | 3,453 |
| Net cash provided by (used in) operating activities | 22,205 | 4,465 |
| Purchases of property and equipment | 9 | 181 |
| Proceeds from sales of marketable securities | 11,800 | 45,938 |
| Purchases of marketable securities | 5,224 | 41,694 |
| Upfront license payment for acquired in-process research & development | 15,000 | - |
| Net cash (used in) provided by investing activities | -8,433 | 4,063 |
| Proceeds from issuance of shares off the at-the-market offering program | 0 | 0 |
| Proceeds from stock option exercises and employee share purchase plan | 2,507 | 1,672 |
| Net cash provided by financing activities | 2,507 | 1,672 |
| Effect of foreign currency exchange rate changes on cash and cash equivalents | 132 | 1,831 |
| Net change in cash and cash equivalents | 16,411 | 12,031 |
| Cash and cash equivalents at beginning of period | 51,371 | - |
| Cash and cash equivalents at end of period | 79,813 | - |